Connie Cho

Associate Director, CMC Analytical Development at Regulus Therapeutics, Inc.

Connie Cho

Connie Cho

Associate Director, CMC Analytical Development at Regulus Therapeutics, Inc.

Overview
RelSci Relationships

34

Contact Data
Trying to get in touch with Connie Cho? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Connie Cho likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Financial & Accounting Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Senior Vice President, Human Capital at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Secretary & Vice President-Legal Affairs at Regulus Therapeutics, Inc.

Relationship likelihood: Average

President & Chief Executive Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Chief Research & Development Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Chief Executive Officer at AmpliPhi Biosciences Corp.

Relationship likelihood: Average

Founder at SENTÉ, Inc. (California)

Relationship likelihood: Average

Former Senior Research Investigator & Oncology Therapeutic Area Head, Oncology Research Unit at Pfizer, Inc.

Relationship likelihood: Average

Senior Vice President, General Counsel, Business Development & Corporate Secretary at Heron Therapeutics, Inc.

Relationship likelihood: Average

Former Chief Medical Officer at Regulus Therapeutics, Inc.

Relationship likelihood: Average

Paths to Connie Cho
Potential Connections via
Relationship Science
You
Connie Cho
Associate Director, CMC Analytical Development at Regulus Therapeutics, Inc.
Career History
Associate Director, CMC Analytical Development
Current

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

Other Affiliations

Connie Cho is affiliated with Regulus Therapeutics, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Connie Cho. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Connie Cho's profile does not indicate a business or promotional relationship of any kind between RelSci and Connie Cho.
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/person/connie-cho-243486652
  • https://relationshipscience.com/person/connie-cho-243486652